Intrigued by this statementCommenting on the interim IVIG data, Bill Bees, Vice President of Plasma Technologies at Prometic Plasma Resources Inc., stated: “In addition to confirming our ability to produce commercial quality IVIG, the positive clinical results confirm Prometic’s hyperimmune product platform. By actively pursuing the manufacture of specialty IgGs using our proprietary process and leveraging our speciality plasma collection center, we continue to play a leading role in targeting and addressing unmet medical needs requiring plasma-derived therapeutics”.
It will be interesting to know PLI's strategy in the hyperimmune area as this is a very lucrative market?